Printer Friendly

AstraZeneca and Francis Crick Institute sign research agreement.

M2 PHARMA-May 24, 2017-AstraZeneca and Francis Crick Institute sign research agreement

(C)2017 M2 COMMUNICATIONS

A new research agreement has been signed by the Francis Crick Institute and AstraZeneca (LON: AZN), the institute revealed on Tuesday.

Over a five-year period, researchers from AstraZeneca and the Crick will work together on early-stage research that could go on to help create new treatments and health innovations in the future.

The aim of the collaboration is to use each other's expertise to stimulate and accelerate basic research into the understanding of human health across a range of cancers, cardiovascular and respiratory diseases.

A research fund will be established as a result of the open research agreement. The fund will include contributions from AstraZeneca, Cancer Research UK, as well as money from an existing Medical Research Council translational research award to the Crick. The research fund will be used to support Crick researchers in projects at an early 'pre-competitive' stage of development.

Under the terms of the agreement, Crick researchers will have access to AstraZeneca compounds, as well as a range of technology platforms.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 24, 2017
Words:191
Previous Article:Brexit spells trouble for British biotech firms.
Next Article:Igenica Biotherapeutics' immuno-oncology assets acquired by Pierre Fabre.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters